The current good manufacturing practice (cGMP) site will expand Thermo Fisher's clinical and commercial capabilities for plasmid DNA, a raw material that is used to develop and manufacture cell and gene-based therapies, including cancer treatments and messenger RNA (mRNA) vaccines.

Also, the 67,000-sq-ft facility will produce large-scale plasmid DNA as a primary drug substance for DNA therapies. The facility will be equipped with equipment up to 1,000-L scale, digital connectivity, and data visibility capabilities.

The expansion will complement viral vector services that the company provides from its facilities in Cambridge, MA, Lexington, MA, Plainville, MA, and Alachua, FL, as well as its cell therapy manufacturing facility in Princeton, NJ, and cryocenter in Germany.

It is expected to be completed in the first half of 2021 and will add approximately 150 new jobs in the next year.

Thermo Fisher expands manufacturing footprint
Thermo Fisher Scientific is expanding its footprint in North America and Europe in sterile drug product development and commercial manufacturing.

Thermo Fisher unveils new isotopic mass spectrometry system
Thermo Fisher has announced it has designed a new high-resolution mass spectrometry system for accurately extracting isotopic data from very small samples.

Thermo Fisher partners with Northeastern University
Thermo Fisher Scientific and Northeastern University have partnered to advance analytical capabilities and boost the biopharmaceutical industry.

Thermo Fisher expands collaboration with Symphogen
Thermo Fisher Scientific has expanded its collaboration with Symphogen to support that company's efforts to provide therapeutic proteins for biopharmaceutical...

Thermo Fisher expands Direct-to-Patient clinical trial service
Thermo Fisher Scientific said it has expanded its Direct-to-Patient clinical trial service to enable clinical trial medications to be delivered directly...